Evidence map›Paper›PMID 39718030›Full record

ArticleDisease models & mechanisms2024

Impact of distinct dystrophin gene mutations on behavioral phenotypes of Duchenne muscular dystrophy.

Amel Saoudi, Manuela D Mitsogiannis, Faouzi Zarrouki, Claire Fergus, Erwina Stojek, Silvia Talavera, Dervla Moore-Frederick, Vincent P Kelly, Aurélie Goyenvalle, Federica Montanaro and 4 more

Abstract read
In one paragraph

Article in Disease models & mechanisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Amel SaoudiCNRS, Institut des Neurosciences Paris-Saclay, Université Paris-Saclay, 91400 Saclay, France.
Manuela D MitsogiannisTranspharmation Ireland Ltd, Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Dublin, Ireland.ORCID 0000-0002-1551-9150
Faouzi ZarroukiCNRS, Institut des Neurosciences Paris-Saclay, Université Paris-Saclay, 91400 Saclay, France.
Claire FergusSchool of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Dublin, Ireland.ORCID 0009-0000-9081-1736
Erwina StojekTranspharmation Ireland Ltd, Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Dublin, Ireland.ORCID 0000-0001-5966-722X
Silvia TalaveraTranspharmation Ireland Ltd, Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Dublin, Ireland.
Dervla Moore-FrederickTranspharmation Ireland Ltd, Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Dublin, Ireland.
Vincent P KellySchool of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Dublin, Ireland.ORCID 0000-0001-7067-5407
Aurélie GoyenvalleUVSQ, Inserm, END-ICAP, Université Paris-Saclay, Versailles, France.ORCID 0000-0003-3938-1165
Federica MontanaroGreat Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre, University College London, London, United Kingdom.ORCID 0000-0002-3338-0498
Francesco MuntoniGreat Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre, University College London, London, United Kingdom.ORCID 0000-0002-9102-5232
Jack A PrendervilleTranspharmation Ireland Ltd, Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Dublin, Ireland.
Ewa SokolowskaTranspharmation Ireland Ltd, Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Dublin, Ireland.
Cyrille VaillendCNRS, Institut des Neurosciences Paris-Saclay, Université Paris-Saclay, 91400 Saclay, France.ORCID 0000-0002-8783-8185

Funding

Centre National de la Recherche ScientifiqueHorizon 2020 Framework Programme 847826Ministère de l'Enseignement supérieur, de la Recherche et de l'InnovationTranspharmation Poland LtdUniversité Paris-Saclay
6 · The paper itself

Abstract

The severity of brain comorbidities in Duchenne muscular dystrophy (DMD) depends on the mutation position within the DMD gene and differential loss of distinct brain dystrophin isoforms (i.e. Dp427, Dp140, Dp71). Comparative studies of DMD mouse models with different mutation profiles may help to understand this genotype-phenotype relationship. The aim of this study was (1) to compare the phenotypes due to Dp427 loss in mdx5cv mice to those of mdx52 mice, which concomitantly lack Dp427 and Dp140; and (2) to evaluate replicability of phenotypes in separate laboratories. We show that mdx5cv mice displayed impaired fear conditioning and robust anxiety-related responses, the severity of which was higher in mdx52 mice. Depression-related phenotypes presented variably in these models and were difficult to replicate between laboratories. Recognition memory was unaltered or minimally affected in mdx5cv and mdx52 mice, at variance with the cognitive deficits described in the original Dp427-deficient mdx mouse, suggesting a difference related to its distinct genetic background. Our results confirm that Dp140 loss may increase the severity of emotional disturbances, and provide insights on the limits of the reproducibility of behavioral studies in DMD mouse models.

Indexed as

Behavior, AnimalDystrophinFearMice, Inbred mdxMuscular Dystrophy, DuchenneMutationPhenotypeAnimalsAnxietyDisease Models, AnimalMaleMiceMice, Inbred C57BLDystrophinBrain dystrophinCognitionDp140Emotional reactivityMdx52Mdx 5cv

Identifiers

PMID39718030
PMCPMC11698058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.